<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0005505'>Refractory anemia</z:hpo> and <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> are two <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) subgroups linked with <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> is a group of <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> oncohematological <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by ineffective hematopoiesis, blood cytopenias, and progression of the disease toward <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this study was to search for plasma proteome changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: A total of 26 patient and healthy donor plasma samples were depleted of fourteen high-abundant plasma proteins, separated with 2D electrophoresis, and statistically processed with Progenesis SameSpots software </plain></SENT>
<SENT sid="4" pm="."><plain>55 significantly differing spots were observed and corresponded to 39 different proteins identified by nanoLC-MS/MS </plain></SENT>
<SENT sid="5" pm="."><plain>Changes in the fragments of the inter-alpha-trypsin inhibitor heavy chain H4 protein were observed </plain></SENT>
<SENT sid="6" pm="."><plain>Using mass spectrometry-based relative label-free quantification of tryptic <z:chebi fb="7" ids="16670">peptides</z:chebi>, there were differences in alpha-2-HS-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> <z:chebi fb="7" ids="16670">peptides</z:chebi>, while no differences were observed between the control and patient sample groups for <z:chebi fb="1" ids="50211">retinol</z:chebi>-binding protein 4 peptides </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: This study describes plasma proteome changes associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Changes observed in the inter-alpha-trypsin inhibitor heavy chain H4 fragments were in agreement with our previous studies of other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subgroups: refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts subtype 1 </plain></SENT>
<SENT sid="9" pm="."><plain>Mass spectrometry-based relative quantification of <z:chebi fb="1" ids="50211">retinol</z:chebi>-binding protein 4 peptides has shown that there are differences in the modification of this protein between <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts subtype 1 patients and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> and <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Alpha-2-HS-<z:chebi fb="2" ids="17089">glycoprotein</z:chebi> seems to be a new potential <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> biomarker candidate </plain></SENT>
</text></document>